Indivior Pharmaceuticals Q1 revenue rises 19%, beats estimates

Indivior Pharmaceuticals

30/04/2026 12:12

Overview

U.S. opioid treatment maker's Q1 revenue rose 19% yr/yr, beating analyst expectations

Record adjusted EBITDA for Q1 more than doubled yr/yr

Company repurchased $125 mln in shares during Q1

Outlook

Indivior now expects 2026 adjusted EBITDA of $620 mln-$660 mln, up from $535 mln-$575 mln

Result Drivers

SUBLOCADE GROWTH - 32% yr/yr increase in SUBLOCADE net revenue, driven by 20% growth in dispense unit volume and record new patient starts

PRICE/MIX AND ADJUSTMENTS - Net revenue benefited from more favorable price/mix and gross-to-net adjustments

Company press release: ID:nGNX1yndDB

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$317 mln
$272.84 mln (5 Analysts)
Q1 Net Income
$89 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Indivior Pharmaceuticals, Inc is $49.00, about 43.5% above its April 29 closing price of $34.15

The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 13 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)